GCMB- Master Regulator of Parathyroid Function
GCMB-甲状旁腺功能的主调节器
基本信息
- 批准号:7895882
- 负责人:
- 金额:$ 51.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-20 至 2012-06-30
- 项目状态:已结题
- 来源:
- 关键词:AblationAdultAffectAllelesBiochemicalBirthBloodCalciumCell DeathCell MaintenanceCell ProliferationCellsCollaborationsDataDefectDevelopmentDiseaseDisease of parathyroid glandsEmbryoEmbryonic DevelopmentEndocrine System DiseasesExonsFailureGene ExpressionGene MutationGene TargetingGenesGeneticGenetic RecombinationGoalsGrowthGrowth and Development functionHealthHomeostasisHumanHyperparathyroidismHypocalcemia resultHypoparathyroidismKnowledgeLaboratoriesLeadLeftLifeLongevityMaintenanceMessenger RNAMetabolic DiseasesMetabolismMineralsModelingMolecularMolecular GeneticsMusMutant Strains MiceMutationNeurogliaParathyroid HormonesParathyroid glandPatientsPhenotypePregnancyProceduresRegulationRegulator GenesResearchResearch PersonnelResearch Project GrantsReverse Transcriptase Polymerase Chain ReactionRoleSequence AnalysisSeriesSerumSerum Phosphorus LevelSiteTechniquesTerminator CodonTestingTimeTransgenic MiceTransgenic OrganismsWorkbasebonecell growthchromatin immunoprecipitationgland developmenthuman PTH proteinhuman diseasein vivoinsightmouse modelnovelparathyroid hyperplasiapostnatalprecursor cellrecombinaseresearch studyskeletaltranscription factor
项目摘要
The long-term objective of our research is to characterize the molecular and genetic role of GCM2 in controlling parathyroid gland development during embryogenesis and parathyroid cell maintenance after birth. Studies in mice have shown that parathyroid formation is under the control of the Gcm2 gene (glial cell missing 2), which encodes a novel transcription factor that is expressed exclusively in the developing and mature parathyroid gland. Studies from our laboratory and by others have shown that genetic mutations that inactivate GCM2 in humans cause hypoparathyroidism, a metabolic disorder characterized by severe hypocalcemia and hyperphosphatemia due to deficiency of parathyroid hormone (PTH). Genetic ablation of Gcm2 in mouse embryos causes a similar phenotype with parathyroid aplasia. These observations establish
GCM2 as the master control gene for embryological development of parathyroid glands, but leave unanswered questions about the role of Gcm2 during late gestation and during postnatal life. We hypothesize that expression of Gcm2 in the parathyroid is necessary throughout life to maintain parathyroid cell mass, and that lack of Gcm2 will induce parathyroid cell death. We propose to use mouse models that we have developed that enable us to genetically delete the Gcm2 gene conditionally, in a temporally and spatially controlled manner, to identify the genes that are controlled by Gcm2 action and the effect of loss of Gcm2 on growth and function of mature parathyroid cells. Mice with conditional Gcm2 alleles will also allow us to determine whether ablation of Gcm2
late in life can "rescue" mice that have parathyroid disorders that replicate the human condition primary hyperparathyroidism. The specific aims of this proposal are: 1. to characterize our mice with conditional Gcm2 alleles; 2. to determine the consequences of timed deletion of Gcm2 on parathyroid cell growth and function in normal mice and mice with parathyroid hyperplasia; and 3. to identify genes that are controlled by Gcm2, using a combination of microarray expression analysis and chromatin immunoprecipitation. Together, these experiments will elucidate the role of GCM2 in regulating parathyroid growth and development across the lifespan, and provide critical new information regarding the genes that are regulated by Gcm2. Ultimately, this information may yield new strategies for regulating parathyroid growth and/or function in patients with parathyroid disorders.
我们研究的长期目标是表征GCM2在胚胎发生过程中控制甲状旁腺发育和出生后甲状旁腺细胞维持过程中的分子和遗传作用。在小鼠中的研究表明,甲状旁腺形成在GCM2基因的控制下(神经胶质细胞缺失2),该基因编码了一种新型的转录因子,该因子仅在发育和成熟的甲状旁腺中表达。我们实验室和其他实验室的研究表明,在人类中灭活GCM2的遗传突变会引起甲状腺功能低下,这是一种因甲状旁腺激素(PTH)而导致严重低钙血症和高磷酸血症的代谢疾病。 GCM2在小鼠胚胎中的遗传消融会导致甲状旁腺染色体类似的表型。这些观察结果
GCM2是甲状旁腺的胚胎发展基因的主要控制基因,但对GCM2在妊娠后期和产后生活中的作用留下了未解决的问题。我们假设GCM2在甲状旁腺中的表达是维持甲状旁腺细胞量的必要条件,而缺乏GCM2会诱发甲状旁腺细胞死亡。我们建议使用已经开发的小鼠模型,使我们能够以时间和空间控制的方式有条件地删除GCM2基因,以识别受GCM2作用控制的基因,以及GCM2丧失对成熟甲状旁腺细胞生长和功能的影响。带有条件GCM2等位基因的小鼠还将允许我们确定GCM2的消融
生命后期可以“营救”患有甲状旁腺功能障碍的小鼠,可复制人类病情原发性甲状旁腺功能亢进症。该提案的具体目的是:1。用条件GCM2等位基因表征我们的小鼠; 2。确定GCM2定时缺失对甲状旁腺增生的正常小鼠和小鼠的甲状旁腺细胞生长和功能的后果; 3。使用微阵列表达分析和染色质免疫沉淀的组合来识别由GCM2控制的基因。总之,这些实验将阐明GCM2在调节整个寿命的甲状旁腺生长和发育中的作用,并提供有关GCM2调节基因的关键新信息。最终,这些信息可能会产生新的策略,以调节甲状旁腺疾病患者的甲状旁腺增长和/或功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL ALAN LEVINE其他文献
MICHAEL ALAN LEVINE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL ALAN LEVINE', 18)}}的其他基金
Repurposing rifampin to reduce elevated levels of blood and urine calcium in patients with inactivating mutations of CYP24A1
重新利用利福平可降低 CYP24A1 失活突变患者的血钙和尿钙水平升高
- 批准号:
10581278 - 财政年份:2022
- 资助金额:
$ 51.01万 - 项目类别:
Repurposing rifampin to reduce elevated levels of blood and urine calcium in patients with inactivating mutations of CYP24A1
重新利用利福平可降低 CYP24A1 失活突变患者的血钙和尿钙水平升高
- 批准号:
9388011 - 财政年份:2017
- 资助金额:
$ 51.01万 - 项目类别:
Repurposing rifampin to reduce elevated levels of blood and urine calcium in patients with inactivating mutations of CYP24A1
重新利用利福平可降低 CYP24A1 失活突变患者的血钙和尿钙水平升高
- 批准号:
9980393 - 财政年份:2017
- 资助金额:
$ 51.01万 - 项目类别:
Repurposing rifampin to reduce elevated levels of blood and urine calcium in patients with inactivating mutations of CYP24A1
重新利用利福平可降低 CYP24A1 失活突变患者的血钙和尿钙水平升高
- 批准号:
10170333 - 财政年份:2017
- 资助金额:
$ 51.01万 - 项目类别:
The Role of GCM2 in Parathyroid Gland Homeostasis
GCM2 在甲状旁腺稳态中的作用
- 批准号:
8437490 - 财政年份:2012
- 资助金额:
$ 51.01万 - 项目类别:
The Role of GCM2 in Parathyroid Gland Homeostasis
GCM2 在甲状旁腺稳态中的作用
- 批准号:
8687644 - 财政年份:2012
- 资助金额:
$ 51.01万 - 项目类别:
The Role of GCM2 in Parathyroid Gland Homeostasis
GCM2 在甲状旁腺稳态中的作用
- 批准号:
8871435 - 财政年份:2012
- 资助金额:
$ 51.01万 - 项目类别:
The Role of GCM2 in Parathyroid Gland Homeostasis
GCM2 在甲状旁腺稳态中的作用
- 批准号:
8549201 - 财政年份:2012
- 资助金额:
$ 51.01万 - 项目类别:
GCMB- Master Regulator of Parathyroid Function
GCMB-甲状旁腺功能的主调节器
- 批准号:
7729158 - 财政年份:2009
- 资助金额:
$ 51.01万 - 项目类别:
CLONING OF THE PSEUDOHYPOPARATHYROIDISM TYPE 1B GENE
1B 型假性甲状旁腺功能减退症基因的克隆
- 批准号:
6312282 - 财政年份:1999
- 资助金额:
$ 51.01万 - 项目类别:
相似国自然基金
成人免疫性血小板减少症(ITP)中血小板因子4(PF4)通过调节CD4+T淋巴细胞糖酵解水平影响Th17/Treg平衡的病理机制研究
- 批准号:82370133
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
儿童期受虐经历影响成年人群幸福感:行为、神经机制与干预研究
- 批准号:32371121
- 批准年份:2023
- 资助金额:50.00 万元
- 项目类别:面上项目
依恋相关情景模拟对成人依恋安全感的影响及机制
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
依恋相关情景模拟对成人依恋安全感的影响及机制
- 批准号:32200888
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
生活方式及遗传背景对成人不同生命阶段寿命及死亡的影响及机制的队列研究
- 批准号:82173590
- 批准年份:2021
- 资助金额:56.00 万元
- 项目类别:面上项目
相似海外基金
Role of Frizzled 5 in NK cell development and antiviral host immunity
Frizzled 5 在 NK 细胞发育和抗病毒宿主免疫中的作用
- 批准号:
10748776 - 财政年份:2024
- 资助金额:
$ 51.01万 - 项目类别:
Investigating the coordinated endothelial-epithelial interactions in adult hair cycle of mouse skin
研究小鼠皮肤成年毛发周期中协调的内皮-上皮相互作用
- 批准号:
10674132 - 财政年份:2023
- 资助金额:
$ 51.01万 - 项目类别:
The Role of Bone Sialoprotein in Modulating Periodontal Development and Repair
骨唾液酸蛋白在调节牙周发育和修复中的作用
- 批准号:
10752141 - 财政年份:2023
- 资助金额:
$ 51.01万 - 项目类别:
In vivo feasibility of a smart needle ablation treatment for liver cancer
智能针消融治疗肝癌的体内可行性
- 批准号:
10699190 - 财政年份:2023
- 资助金额:
$ 51.01万 - 项目类别:
LRP1 as a novel regulator of CXCR4 in adult neural stem cells and post-stroke response
LRP1 作为成体神经干细胞和中风后反应中 CXCR4 的新型调节剂
- 批准号:
10701231 - 财政年份:2023
- 资助金额:
$ 51.01万 - 项目类别: